Thursday, February 5, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Ares Commercial Real Estate Downgraded to Underperform

Elaine Mendonca by Elaine Mendonca
March 4, 2024
in Breaking News
0
Finance_ Stock Charts (2)
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

On March 4, 2024, Ares Commercial Real Estate (NYSE:ACRE) faced a downgrade from Buy to Underperform by B of A Securities analyst Eric Dray. The price target was also reduced from $11 to $7. Concerns about declining asset values in the commercial real estate sector, especially impacting ACRE’s office properties and multifamily markets, led to this decision. The company’s financial situation has been negatively affected by decreasing property values, potential credit losses, and challenges in refinancing loans maturing in 2024 and 2025. Despite offering a high yield and having a strong investment platform, the current risks associated with ACRE outweigh the potential rewards.

Ares Commercial Real Estate Corporation (ACRE) Stock Analysis and Performance Review – March 4, 2024

On March 4, 2024, Ares Commercial Real Estate Corporation (ACRE) saw some interesting movements in its stock performance. ACRE is currently trading near the bottom of its 52-week range and below its 200-day simple moving average, indicating possible downward pressure.

Despite this, ACRE saw a positive price change on March 4th, with shares increasing by $0.22 (2.92%) to close at $7.76. However, the stock dropped by $0.16 in pre-market trading, suggesting volatility.

Investors and analysts will monitor ACRE’s performance to see if the positive momentum can be sustained. Stock prices can fluctuate, so it will be interesting to see how ACRE performs in the coming days. Conducting research and consulting with a financial advisor before making investment decisions is recommended.

ACRE Stock Performance Review: Mixed Results for March 4, 2024

On March 4, 2024, ACRE stock showed mixed performances based on the latest financial data provided by CNN Money. The company reported a total revenue of $192.08 million for the past year, which represents an 11.13% increase compared to the previous year. However, the total revenue remained flat at $47.51 million for the last quarter.

In terms of net income, ACRE reported a net loss of $38.87 million for the past year, which is a significant decrease of 230.49% compared to the previous year. On the other hand, the net loss slightly improved to $39.41 million for the last quarter, showing a 0.0% increase compared to the previous quarter.

Earnings per share (EPS) for ACRE also showed a negative trend, with a reported EPS of -$0.72 for the past year, representing a decrease of 225.31% compared to the previous year. The EPS remained the same at -$0.73 for the last quarter, showing no improvement compared to the previous quarter.

Overall, the financial performance of ACRE stock on March 4, 2024, reflects a mixed picture. Investors may want to closely monitor the company’s financial performance and future outlook to make informed decisions about investing in ACRE stock.

Tags: ACRE
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Neurotechnology

Apple Unveils New MacBook Air Models with M3 Chip and Impressive Features

Biopharmaceutical

Groundbreaking Results of Nanobody Sonelokimab in Treating Hidradenitis Suppurativa

Digital platforms

Auddias Strategic Acquisition Plan Targeting Growth and Revenue Expansion

Recommended

Gerresheimer Stock

Gerresheimer Shares Plunge Amid Deepening Crisis

4 months ago
Alphabet Stock

Regulatory Pressure Mounts on Alphabet as UK Designates Search Dominance

4 months ago
Technology Data analytics stock Trading (1)

Revolutionizing Ad Monetization Brightcove and Google Ad Manager Join Forces

2 years ago
MMP stock news

Yousif Capital Management Reduces Holdings in Alarm.com, Inc. – Analyzing Impact on Future Prospects

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Viking Therapeutics: Investors Await Key Clinical Updates in Forthcoming Report

Solana Faces Billions in Potential Token Supply Releases

CureVac Delisted Following BioNTech Acquisition Completion

Strategic Robotics Partnership Signals New Growth Phase for EOS Defence

NexPoint Residential Trust Sets Date for Annual and Q4 2025 Results

PC Connection Set to Report Full-Year and Fourth Quarter Earnings

Trending

CrowdStrike Stock
Analysis

CrowdStrike Shares Face Headwinds Amid Mixed Signals

by Andreas Sommer
February 5, 2026
0

The investment case for cybersecurity leader CrowdStrike is currently being shaped by conflicting developments. Positive legal news...

NCR Stock

NCR Voyix Charts a Course Toward Cloud-Centric Growth

February 5, 2026
Rolls Royce Stock

Rolls-Royce Shares: A Pivotal Period for Growth and Diversification

February 5, 2026
Viking Therapeutics Stock

Viking Therapeutics: Investors Await Key Clinical Updates in Forthcoming Report

February 5, 2026
Solana Stock

Solana Faces Billions in Potential Token Supply Releases

February 5, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • CrowdStrike Shares Face Headwinds Amid Mixed Signals
  • NCR Voyix Charts a Course Toward Cloud-Centric Growth
  • Rolls-Royce Shares: A Pivotal Period for Growth and Diversification

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com